Amicogen, Inc. (KOSDAQ:092040)

-57.32% (1Y)

Market Cap	199.81B
Revenue (ttm)	173.60B
Net Income (ttm)	-52.79B
Shares Out	54.82M
EPS (ttm)	-961.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	234,612
Average Volume	296,501
Open	3,685.00
Previous Close	3,725.00
Day's Range	3,545.00 - 3,750.00
52-Week Range	3,075.00 - 9,200.00
Beta	1.05
RSI	47.48
Earnings Date	Mar 16, 2025

About Amicogen

Amicogen, Inc. operates as an industrial biotechnology company in South Korea and internationally. The company develops, produces, and sells of enzymes and new materials; and produces food-related additives and health functional food. It manufactures and sells of biopharmaceutical materials and resins for purifying pharmaceutical proteins and health and beauty products. In addition, the company offers oral incurable and rare disease treatments, as well as manufactures and sells of pharmaceutical raw materials, animal drugs, human drugs, etc. Th...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 225
• Stock Exchange: KOSDAQ
• Ticker Symbol: 092040

Financial Performance

In 2024, Amicogen's revenue was 173.60 billion, an increase of 8.57% compared to the previous year's 159.90 billion. Losses were -52.79 billion, 126.7% more than in 2023.